Recently Added Drugs

1. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559523 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Method of treating emesis

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357935

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2039

(16 years from now)

US11464923

(Pediatric)

TEVA PHARM Inhaler system
Dec, 2040

(17 years from now)

US11439777

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Nov, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

3. List of Atorvaliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(14 years from now)

Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

4. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564917 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
M (M) Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

5. List of Austedo Xr drug patents

AUSTEDO XR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9550780 TEVA Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179386 TEVA Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(14 years from now)

US10959996 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11311488 TEVA Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
Jun, 2041

(18 years from now)

US11564917 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11446291 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

US11357772 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(12 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

48

United States

11

Japan

9

China

8

Australia

7

European Union

6

Hong Kong

6

Canada

5

Spain

3

Brazil

3

Korea, Republic of

3

South Africa

3

Israel

3

Denmark

2

Portugal

2

Singapore

2

Croatia

2

New Zealand

2

Argentina

2

Mexico

2

EA

2

Lithuania

2

Hungary

2

Poland

2

Chile

1

Colombia

1

Norway

1

Peru

1

Taiwan, Province of China

1

India

1

Cyprus

1

Slovenia

1

RS

6. List of Brenzavvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(5 years from now)

US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(9 years from now)

US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(8 years from now)

US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

7. List of Brukinsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11591340 BEIGENE NA
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 2023-11-15

Market Authorisation Date: 14 November, 2019

Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment of adult patients with chronic lymphocytic leukemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Treatment of adult patients with small lymphocytic lymphoma

Dosage: CAPSULE;ORAL

More Information on Dosage

8. List of Dyanavel Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590228 TRIS PHARMA INC NA
Sep, 2036

(13 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

9. List of Dyanavel Xr 10 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590081 TRIS PHARMA INC NA
Sep, 2038

(15 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

10. List of Emerphed drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571398 NEXUS PHARMS NA
May, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 17 April, 2020

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of EMERPHED before it's patent expiration?
More Information on Dosage

11. List of Evrysdi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2029
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 2024-08-07

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

12. List of Hetlioz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's patent expiration?
More Information on Dosage

13. List of Hetlioz Lq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

14. List of Jatenzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564933 TOLMAR Methods of treating testosterone deficiency
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: CAPSULE;ORAL

More Information on Dosage

15. List of Jaypirca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10695323 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10342780 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918622 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10464905 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

Drugs and Companies using PIRTOBRUTINIB ingredient

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

16. List of Jesduvroq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(14 years from now)

US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage: TABLET;ORAL

More Information on Dosage

17. List of Kalydeco drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 17 March, 2015

Treatment: Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916

Dosage: GRANULE;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

18. List of Kalydeco drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 31 January, 2012

Treatment: Treatment of cf in a patient age 6 years and older who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916

Dosage: TABLET;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

19. List of Lenvima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090386 EISAI INC Method for suppressing bitterness of quinoline derivative
Feb, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
M (M) Dec 19, 2024
New Indication (I) Aug 10, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: Treatment with lenvima by administering lenvima as a suspension

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's patent expiration?
More Information on Dosage

20. List of Liletta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571328 MEDICINES360 NA
Sep, 2040

(17 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

21. List of Mekinist drug patents

Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7378423

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Nov, 2027

(4 years from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(2 years from now)

US8580304

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(9 years from now)

US9155706

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(9 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(8 years from now)

US9271941

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(9 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(8 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(10 years from now)

US9399021

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
New Indication (I) Jun 22, 2025
Pediatric Exclusivity (PED) Oct 30, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

22. List of Onureg drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571436 BRISTOL NA
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 1, 2023
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's patent expiration?
More Information on Dosage

23. List of Opzelura drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571425 INCYTE CORP NA
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Mar 21, 2025

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

24. List of Orkambi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Sep 2, 2025
Orphan Drug Exclusivity (ODE) Aug 7, 2025
New Patient Population (NPP) Sep 2, 2025

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Market Authorisation Date: 07 August, 2018

Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for the f508del mutation in the cftr gene using the composition recited in claim 1 of us 11564916

Dosage: GRANULE;ORAL

More Information on Dosage

25. List of Orserdu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10745343 STEMLINE THERAP Polymorphic forms of RAD1901-2HCl
Jan, 2038

(14 years from now)

US10071066 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer; Treatment of an er-positive breast cancer following at least one line of endocrine therapy

Dosage: TABLET;ORAL

More Information on Dosage

26. List of Prevduo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456354 SLAYBACK PHARMA LLC Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(15 years from now)

US11110054 SLAYBACK PHARMA LLC Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(15 years from now)

Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient

Market Authorisation Date: 23 February, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

27. List of Qinlock drug patents

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11576903 DECIPHERA PHARMS NA
Dec, 2040

(17 years from now)

US11576904 DECIPHERA PHARMS NA
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 2024-05-15

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 arthralgia while being administered ripretinib daily

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559637 NORTON WATERFORD Inhalers and related methods
Jul, 2039

(16 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

29. List of Relyvrio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583542 AMYLYX NA
Jul, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 2026-09-29

Market Authorisation Date: 29 September, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

30. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropane; Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having mild, moderate, or severe renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

31. List of Symdeko (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027
New Chemical Entity Exclusivity (NCE) Feb 12, 2023

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 2022-02-12

Market Authorisation Date: 12 February, 2018

Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the composition recited in us 11564916 claim 1

Dosage: TABLET;ORAL

More Information on Dosage

32. List of Synjardy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 August, 2015

Treatment: Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of io mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's patent expiration?
More Information on Dosage

SYNJARDY family patents

15

United States

4

Japan

3

China

3

Israel

2

Philippines

2

Korea, Republic of

2

Canada

2

Australia

2

European Union

1

Portugal

1

Spain

1

Croatia

1

New Zealand

1

Mexico

1

Hong Kong

1

EA

1

Lithuania

1

Poland

1

Chile

1

Finland

1

RS

1

Denmark

33. List of Synjardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

SYNJARDY XR family patents

15

United States

4

Japan

3

China

3

Israel

2

Philippines

2

Korea, Republic of

2

Canada

2

Australia

2

European Union

1

Portugal

1

Spain

1

Croatia

1

New Zealand

1

Mexico

1

Hong Kong

1

EA

1

Lithuania

1

Poland

1

Chile

1

Finland

1

RS

1

Denmark

34. List of Tafinlar drug patents

Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7994185

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(7 years from now)

US8415345

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(7 years from now)

US9233956

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Nov, 2029

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(8 years from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(2 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(8 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
New Indication (I) Jun 22, 2025
Pediatric Exclusivity (PED) Oct 30, 2025

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

35. List of Tlando drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559530 ANTARES PHARMA INC Oral testosterone undecanoate therapy
Nov, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: CAPSULE;ORAL

More Information on Dosage

36. List of Trijardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564886 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(8 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Treatment of a type 2 diabetes patient with insufficient glycemic control despite metformin therapy using a composition comprising and extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's patent expiration?
More Information on Dosage

37. List of Trikafta (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 8, 2024
New Chemical Entity Exclusivity (NCE) Oct 21, 2024
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 2023-10-22

Market Authorisation Date: 21 October, 2019

Treatment: Treatment of cf in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering the composition recited in us 11564916 claim 1

Dosage: TABLET;ORAL

More Information on Dosage

38. List of Xelstrym drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559501 NOVEN PHARMS INC Transdermal amphetamine compositions with low levels of carbamate
Jan, 2042

(18 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: NA

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

39. List of Xhance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11554229 OPTINOSE US INC Nasal administration
Feb, 2036

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

40. List of Zimhi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571518 ADAMIS PHARMS CORP NA
Jun, 2041

(18 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a needle guard; A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syringe

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in